maintain a moat around Copaxone is that it may give it more empathy for branded drug makers when it goes after incumbent products with its own generic versions. Related tickers: ( MNK ) ( ACT ) ( JNJ ) ( MYL ) ( MNTA ) ( NVS ) Post your comment!
Increasing pharmaceutical complexity shines light on Momenta's capabilities.
Likewise, the news is a slight negative for two of the major contenders attempting a generic Copaxone: Momenta Pharmaceuticals and Mylan. Negative shifts in our fair value estimates for both of these companies from potential generic
We’re leaving our fair value estimate for Momenta Pharmaceuticals unchanged after the company reported third-quarter results within our expectations. Momenta reported a net loss of $25.4 million
We're raising our fair value estimate for Momenta Pharmaceuticals to $16 per share after updating our forecast for a potential generic Copaxone launch to 2014 from 2015 following the recent U
decision is a positive for the two major contenders attempting to manufacture generic versions of Copaxone, Mylan MYL and Momenta MNTA . We may slightly increase our fair value estimates for both of these firms as we reevaluate our assumptions. We plan to adjust
Momenta Pharmaceutical's MNTA first-quarter results mostly met our expectations, but volatility from market share shifts and pricing pressure in the generic
We'll likely raise our fair value estimate for Momenta Pharmaceuticals MNTA after the company reported fourth-quarter results and issued a 2013 outlook slightly ahead of our projections. We plan to increase